Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 24, 2021 6:04pm
173 Views
Post# 33601346

The MDGL indicator for NASH partner prospects

The MDGL indicator for NASH partner prospectsI was thinking that the share price of MDGL, the undisputed leader currently in the NASH universe, might  be a good indicator in interest in a NASH partnership that THTX is seeking. With this gold standard NASH stock now below $90 after hitting almost $400 several years back, it is clear sentiment around NASH stocks is at quite a low right now. If MDGL was trading close to $400 right now, the prospects for an attractive partnership deal for THTX in NASH would likely be much better. Hopefully that MDGL indicator recovers nicely in the months ahead but if interest is on the wane for MDGL, the ramifications for an attractive NASH partnership for THTX are likely lower too. When there is no excitement around NASH, there are not likely to be any exciting partnerships formed either.  

I am sure THTX can get some deal done but one has to wonder what terms they will have to accept. If the partner is carrying the load on the trial costs, then we should not expect upfront cash payments of any size.
<< Previous
Bullboard Posts
Next >>